What are the side effects of dasatinib (Sprycel)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Side Effects of Dasatinib (Sprycel)

Dasatinib has several significant side effects including pleural effusions affecting up to 37% of patients, pulmonary arterial hypertension, myelosuppression, and gastrointestinal disturbances, which require careful monitoring and management. 1

Major Side Effects

Pleuro-pulmonary Toxicity

  • Recurrent pleural effusions occur in up to 37% of patients and may develop even after years of treatment 1
  • Pulmonary arterial hypertension (PAH) is rare but serious 1, 2
  • Respiratory failure and pre-existing pleuro-pulmonary or pericardial diseases are strong contraindications to dasatinib use 1
  • Symptoms include shortness of breath, dry cough, and chest pain when breathing deeply 2
  • Fluid retention can occur in multiple body compartments (lungs, heart sac, stomach cavity) 2, 3

Hematological Toxicity

  • Myelosuppression affects all three blood cell lineages 1:
    • Neutropenia (grade 3-4): 19.4% in first-line treatment
    • Thrombocytopenia (grade 3-4): 17.4% in first-line treatment
    • Anemia (grade 3-4): 11.5% in first-line treatment
  • Higher rates of myelosuppression occur in advanced phases of CML 1
  • Bleeding risk is increased, particularly gastrointestinal bleeding (17% across all phases) 1, 4
  • Risk factors for bleeding include thrombocytopenia and advanced phase CML 4

Gastrointestinal Side Effects

  • Generally well-tolerated compared to other TKIs 1
  • Include nausea, vomiting, diarrhea, and abdominal pain 1
  • Gastrointestinal bleeding risk is higher with dasatinib than other TKIs, especially in second-line treatment (2-5% in chronic phase) 1

Skin Reactions

  • Rash occurs in 11% of patients in first-line treatment, increasing to 33% by 6 years 1
  • Peripheral fluid retention occurs in approximately 26% of patients 1
  • Severe skin reactions with fever, blistering or peeling may occur rarely 2

Cardiovascular Effects

  • Can cause heart problems including abnormal heart rate and heart attack 2
  • Risk of transient ischemic attacks (TIAs) 2
  • Requires monitoring of potassium and magnesium levels 2

Other Notable Side Effects

  • Fatigue and muscle pain are common 2
  • Liver problems may occur, especially in those with prior liver issues 2
  • Tumor lysis syndrome can cause kidney failure and abnormal heart rhythm 2
  • Fertility problems in both males and females 2
  • Growth and development effects in children 2

Management of Side Effects

Pleural Effusions

  • Dose interruption until resolution 3
  • Consider dose reduction to 50 mg daily which has similar efficacy with fewer side effects 1, 5
  • Close monitoring of patients with risk factors for pleural effusion 3

Myelosuppression

  • Regular blood count monitoring 1
  • G-CSF and erythropoietic agents can be used transiently to facilitate recovery 1
  • For grade 3 neutropenia: withhold therapy, treat infection if present, resume at lower dose when resolved 1
  • For grade 4 neutropenia: consider G-CSF and switching to another TKI 1

Gastrointestinal Issues

  • Mild symptoms: symptomatic relief and diet modification 1
  • Severe symptoms: antiemetic and antidiarrheal medications 1
  • For abdominal pain: rule out gastric and pancreatic problems 1
  • Proton-pump inhibitors may help but should be taken 12 hours apart from dasatinib 1

Bleeding Management

  • Careful use of antiplatelet therapy due to platelet dysfunction 1
  • Dasatinib interruption (median 17 days) may be required 4
  • Transfusions may be necessary (72% of bleeding cases) 4

Monitoring Recommendations

  • Regular blood count monitoring for myelosuppression 1
  • Cardiac function assessment, especially in patients with pre-existing conditions 1
  • Liver function monitoring 2
  • Patient education about symptoms of fluid retention and pleural effusion 3
  • Close monitoring of patients with risk factors for pleural effusion 1, 3

Dosing Considerations

  • Standard dose is 100 mg once daily for chronic phase CML 1
  • Lower dose of 50 mg daily may be considered due to similar efficacy with fewer side effects 1, 5
  • Dose increase is not recommended 1
  • Dose interruption or reduction may be necessary to manage side effects 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.